Oculis Holding AG shares plunged >35% after both Phase 3 DIAMOND trials for OCS-01 in diabetic macular edema failed primary ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results